Provided by Tiger Trade Technology Pte. Ltd.

Arrowhead Pharmaceuticals

87.11
-0.3600-0.41%
Volume:1.09M
Turnover:94.72M
Market Cap:12.27B
PE:-38.14
High:88.46
Open:87.90
Low:85.94
Close:87.47
52wk High:95.49
52wk Low:20.45
Shares:140.86M
Float Shares:122.00M
Volume Ratio:1.09
T/O Rate:0.89%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2838
EPS(LYR):-0.0122
ROE:-55.21%
ROA:-8.10%
PB:26.36
PE(LYR):-7,144.26

Loading ...

Sep 14, 2021

Statement Of Changes In Beneficial Ownership

4 - Statement of changes in beneficial ownership of securities
Sep 10, 2021

Statement Of Changes In Beneficial Ownership

4 - Statement of changes in beneficial ownership of securities
Aug 27, 2021

Major Issues Report

ARROWHEAD PHARMACEUTICALS, INC.
Jun 25, 2021

Statement Of Changes In Beneficial Ownership

4 - Statement of changes in beneficial ownership of securities
Jun 22, 2021

Major Issues Report

8-K - Current report
Jun 16, 2021

Major Issues Report

8-K - Current report
May 18, 2021

Employee Stock Ownership

S-8 - Securities to be offered to employees in employee benefit plans
May 04, 2021

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
May 04, 2021

Major Issues Report

8-K - Current report
Mar 24, 2021

Major Issues Report

8-K - Current report
Feb 10, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 05, 2021

Correspondence

CORRESP [Cover] - Correspondence
Feb 04, 2021

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Feb 04, 2021

Major Issues Report

8-K - Current report
Jan 27, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Nov 23, 2020

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Nov 23, 2020

Major Issues Report

8-K - Current report
Oct 09, 2020

Major Issues Report

8-K - Current report
Sep 08, 2020

Major Issues Report

8-K - Current report
Aug 05, 2020

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]